Danese and coworkers previously showed that treatment with the non‐RGD‐based peptide ATN161, which blocks both αvβ3 and α5β1 integrins, effectively decreased angiogenesis and improved colitis in the IL‐10−/− mouse model but not in the DSS‐induced model (Danese et al, 2007a). This evidence concerns the gene IL10 and colitis.